Format

Send to

Choose Destination
Clin Med Insights Reprod Health. 2014 Jun 8;8:23-30. doi: 10.4137/CMRH.S14498. eCollection 2014.

Management of Vaginal Atrophy: Implications from the REVIVE Survey.

Author information

1
iWomansHealth, Washington, DC, USA.
2
MacDonald Women's Hospital, Cleveland, OH, USA.
3
Southern California Center for Sexual Health and Survivorship Medicine, Newport Beach, CA, USA.

Abstract

Vulvar and vaginal atrophy (VVA) is a chronic and progressive medical condition common in postmenopausal women. Symptoms of VVA such as dyspareunia, vaginal dryness, irritation, and itching can negatively impact sexual function and quality of life. The REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey assessed knowledge about VVA and recorded attitudes about interactions with healthcare providers (HCPs) and available treatment options for VVA. The REVIVE survey identified unmet needs of women with VVA symptoms such as poor understanding of the condition, poor communication with HCPs despite the presence of vaginal symptoms, and concerns about the safety, convenience, and efficacy of available VVA treatments. HCPs can address these unmet needs by proactively identifying patients with VVA and educating them about the condition as well as discussing treatment preferences and available therapies for VVA.

KEYWORDS:

REVIVE survey; postmenopausal; treatment strategies; vulvar and vaginal atrophy

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center